U.S. stocks surge: Recursion jumps on October 15th as Sanofi drug selection, clinical data updates, and AI-powered drug development drive gains

Recursion October 15 Surge Interpretation

Keywords: Sanofi drug selection, clinical data update, AI drug development

1. On October 15, Sanofi exercised its first option to select a development candidate from the multi-project research collaboration between the two parties. The candidate is a potential first-in-class oral small molecule targeting a dual target associated with inflammatory diseases and is expected to enter Phase I clinical trials in 2027. This selection triggers a $10 million milestone payment, bringing the total upfront and milestone payments for the collaboration to $144 million. Recursion remains eligible to receive more than $300 million in further milestone payments for this project and low double-digit average royalties upon successful commercialization.

2. On October 15, the company disclosed REC-4881 adult FAP data: after 12 weeks of treatment, the median polyp burden decreased by 47%, with 85% of patients still below baseline 12 weeks after discontinuation; the median upper gastrointestinal polyp burden decreased by 55%, with 92% of patients still below baseline 12 weeks after discontinuation. The disease control rate for REC-1245 at doses not less than 45 mg was 91.7% (11/12), with 2 cases of endometrial cancer showing confirmed partial response. The registration trial for REC-4881 is planned to start in the second half of 2027, pending FDA discussion results.

(Disclaimer: This content is a summary generated by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)